|
Zebrafish Models of Cancer
|
ZIA BC 010549
|
$422,717
|
Hickstein, Dennis
|
CCR (NCI)
|
|
Xenograft Model to Study Impact of CRLF2-Ligand in Hispanic Childhood B-ALL
|
5R21CA162259-02
|
$151,804
|
PAYNE, KIMBERLY
|
LOMA LINDA UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-05S2
|
$37,430
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-05
|
$1,396,397
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Vitamin D Analogs as Adjuvants in Chemotherapy of Cancer
|
6R01CA044722-23
|
$191,385
|
Studzinski, George
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
Validation and Development of WEE1 as a therapeutic target in AML
|
1R01CA172385-01A1
|
$314,255
|
PORTER, CHRISTOPHER
|
UNIVERSITY OF COLORADO DENVER
|
|
Validating Syk as a Target for AML Therapy
|
5R01CA140292-05
|
$331,098
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INST
|
|
Using game mechanics to improve outcomes among stem cell transplant survivors
|
3R41CA168107-01S1
|
$149,145
|
McLaughlin, Jeffery
|
RADIANT CREATIVE GROUP, LLC
|
|
University of New Mexico Cancer Center Support
|
3P30CA118100-09S1
|
$75,000
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support
|
3P30CA118100-09S2
|
$112,521
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support
|
5P30CA118100-09
|
$1,808,387
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
Tyrosine kinase inhibitors for the treatment of childhood AML
|
5R01CA138744-04
|
$317,854
|
Baker, Sharyn
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$336,277
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Transponson-based screens for genes involved in acute lymphoblastic Leukemia
|
5R01CA154998-03
|
$283,089
|
Farrar, Michael
|
UNIVERSITY OF MINNESOTA
|
|
Transcriptional regulatory mechanisms in B cell development and leukemogenesis
|
1R01CA178765-01
|
$552,794
|
ROEDER, ROBERT
|
ROCKEFELLER UNIVERSITY
|
|
Toxicity Monitoring on Phase III Trials with Administrative Data
|
5R01CA165277-02
|
$461,557
|
Aplenc, Richard
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Towards defining the functional methylome in acute lymphoblastic leukemia
|
5R00CA132784-05
|
$216,446
|
TAYLOR, KRISTEN
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
|
Therapeutic Targeting of Leukemia-Microenvironmental Interactions
|
1R01CA166280-01A1
|
$318,513
|
CALVI, LAURA
|
UNIVERSITY OF ROCHESTER
|
|
The UT MD Anderson Cancer Center Community Clinical Oncology Program Research Bas
|
5U10CA045809-25
|
$1,885,277
|
FISCH, MICHAEL
|
UT MD ANDERSON CANCER CTR
|
|
The role of PHF6 in T-cell acute lymphoblastic leukemia
|
5R01CA155743-03
|
$312,080
|
Ferrando, Adolfo
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of FBXL4 in T-cell Acute Lymphoblastic Leukemia
|
1F30CA174099-01
|
$41,377
|
Haydu, Julie-Erika
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of ETV6 in T-cell acute lymphoblastic leukemia
|
1R01CA172398-01
|
$332,000
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of CD4+ T Cells in Oncogene Addiction
|
1F32CA177139-01
|
$49,214
|
Casey, Stephanie
|
STANFORD UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
2P30CA060553-19
|
$4,635,678
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-19S1
|
$75,000
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-19S2
|
$50,000
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Requirement for Trib2 in the Maintenance of Acute Myeloid Leukemia
|
5F31CA165813-02
|
$28,581
|
Bailis, Will
|
UNIVERSITY OF PENNSYLVANIA
|
|
The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
|
1R01CA163849-01A1
|
$477,421
|
Justice, Monica
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Impact of Treatment Adherence on A Clinical Biomarker in Pediatric Acute Lymp
|
1F31CA168307-01A1
|
$34,741
|
Rohan, Jennifer
|
UNIVERSITY OF CINCINNATI
|
|
The Glucocorticoid Receptor as Signal Integrator: Studying All Drug Resistance
|
5R00CA149088-05
|
$217,436
|
PUFALL, MILES
|
UNIVERSITY OF IOWA
|
|
The contribution of protein translation to tumorigenesis
|
5R01CA142798-04
|
$359,478
|
Wendel, Hans-Guido
|
SLOAN-KETTERING INST CAN RES
|
|
Temporal and Spatial Control of V(D)J Recombination
|
3R01CA160256-02S1
|
$49,711
|
DESIDERIO, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
Temporal and Spatial Control of V(D)J Recombination
|
5R01CA160256-02
|
$315,981
|
DESIDERIO, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
TAS::75 0849::TAS Incremental Funding
|
261200800001E-51
|
$271,391,560
|
Heimbrook, David
|
SAIC-FREDERICK, INC.
|
|
Targeting to Epigenetic Modications in ALL
|
5R01CA176745-03
|
$378,115
|
ARMSTRONG, SCOTT
|
SLOAN-KETTERING INST CAN RES
|
|
Targeting SYK Tyrosine Kinase to Overcome Radiation Resistance in ALL
|
5R01CA154471-03
|
$312,080
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Targeting SYK Kinase in B-Lineage ALL with CD19-Specific C-61 Nanoparticles
|
5U01CA151837-04
|
$416,542
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Targeting non-classical oncogenes as therapy for T-ALL
|
5R01CA169162-02
|
$312,080
|
Diacovo, Thomas
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Targeting Leukemia Stem Cells with Dietary Selenium
|
5R01CA162665-02
|
$285,029
|
PRABHU, KUMBLE SANDEEP
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
|
Targeting BCL6 in tyrosine kinase-driven leukemia
|
1R01CA169458-01A1
|
$325,602
|
Muschen, Markus
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Targeting an ATM-dependent metabolic pathway and FLT3 for AML therapy
|
5K22CA172757-02
|
$135,968
|
GREGORY, MARK
|
UNIVERSITY OF COLORADO DENVER
|
|
Targeted therapy of ALL with gene-modified central memory T cells
|
5R01CA136551-05
|
$508,741
|
Riddell, Stanley
|
FRED HUTCHINSON CAN RES CTR
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-03
|
$298,427
|
PANG, QISHEN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia
|
5R01CA141303-04
|
$298,935
|
COOPER, LAURENCE
|
UT MD ANDERSON CANCER CTR
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
5U24CA114766-08
|
$1,684,917
|
RAMIREZ, NILSA
|
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
|
|
Significance of Marrow Karyotypes in Inherited Bone Marrow Failure Syndromes
|
ZIA BC 010692
|
$72,768
|
Arthur, Diane
|
CCR (NCI)
|
|
ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia
|
5R00CA151457-04
|
$233,629
|
Tyner, Jeffrey
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Role of TET proteins in myeloid malignancies
|
5R01CA151535-02
|
$347,969
|
Rao, Anjana
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
|
Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia
|
5P01CA129242-05
|
$877,670
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-09
|
$306,016
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL CORPORATION
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|